Sintilimab combined with chemotherapy in advanced pulmonary epithelioid hemangioendothelioma: a case report and translational insights
This case not only underscores the potential of sintilimab in PD-L1-high PEH but also sets a precedent for further exploration of immune checkpoint inhibitors in this rare disease.
Authors
- Tongyuan Li
- Lijun Jing (ORCID: https://orcid.org/0000-0002-3503-2761)
- Liming Zhang (ORCID: https://orcid.org/0000-0002-3500-9043)
- Yongming Wang (ORCID: https://orcid.org/0000-0001-8269-5296)
- H B An (ORCID: https://orcid.org/0009-0008-8213-5019)
- Yang Hao (ORCID: https://orcid.org/0000-0002-9949-7226)
Institutions
- Weifang People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fonc.2025.1575039
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00